Debiopharm

Debiopharm is a family-owned biopharmaceutical company active in drug development and manufacturing of proprietary drugs, diagnostics, and investments,[1] headquartered in Lausanne, Switzerland. It was founded in 1979 by Rolland-Yves Mauvernay.[2]

Debiopharm
TypeSociété Anonyme
IndustryBiopharmaceutical
FoundedLausanne, Switzerland (1979)
FounderDr Rolland-Yves Mauvernay (1922-2017)
HeadquartersLausanne, Switzerland
Area served
Worldwide
Key people
  • Thierry Mauvernay (President)
  • Bertrand Ducrey (CEO Debiopharm International SA)
  • Cédric Sager (CEO Debiopharm Research & Manufacturing SA)
  • Valérie Calvayrac (CEO Debiopharm Investment SA)
Products
Ownerfamily-owned
Websitewww.debiopharm.com

History

Rolland-Yves Mauvernay founded Debiopharm in 1979 in Martigny.[3] In 1981, the Cytotech laboratory was created in Switzerland and after a few years it became Debio Recherche Pharmaceutique (R.P.). Initially, the company worked on interferon and, in 1982, it began to focus on triptorelin, after having acquired the rights for its development from Tulane University.[4] The first marketing authorization for triptorelin, a gonadotropin-releasing hormone GnRH) agonist that is approved for several indications, including advanced prostate cancer and endometriosis was obtained in France in 1986.[5]

In 1989, Debiopharm acquired the license for oxaliplatin from Nagoya City University. oxaliplatin is a diaminocyclohexane (DACH) platin, the drug was first approved in Europe in 1996 and became a worldwide standard treatment in metastatic colorectal cancer.[6]

In September 2004, after having occupied different premises in Lausanne, Debiopharm moved its headquarters to the current address. In 2016, the company employed 350 people.[7]

In March 2021, Merck KGaA announced the acquisition of Debiopharm's xevinapant program in head and neck cancer for 900 million euros.[8]

Subsidiaries

The group works through its subsidiaries:[9]

  • Debiopharm International SA, which in-licenses product candidates or technologies, develops them, and then licenses them to third parties for commercialization;[10]
  • Debiopharm Research and Manufacturing SA, which provides contract manufacturing and contract research services to Debiopharm;[11]
  • Debiopharm Investment SA, which manages the group's money and invests in real estate and in other companies; and[12]
  • Debiopharm Innovation Fund SA, which invests in Digital Health companies and provides strategic funding and guidance for companies with an ambition to improve the patient journey, re-imagine how clinical trials are conducted, along with companies offering digital platforms that support cutting-edge drug technologies.[13]

As of 2010 two drugs had reached the market through its efforts: oxaliplatin for the treatment of cancer, and depot formulations of triptorelin, a gonadotropin-releasing hormone agonist that is approved to treat advanced prostate cancer.[14]

In 2017, Debiopharm acquired a phase 2 drug candidate from ImmunoGen that intends to target Non-Hodgkin lymphoma.[15]

References
  1. Group, Debiopharm. "Debiopharm Group™ to Acquire Products or Companies to Expand Activities at Manufacturing Facility in Martigny (Valais, Switzerland)". www.prnewswire.com. Retrieved 2020-04-10.
  2. Bloomberg profile: Debiopharm Group. Page accessed May 12, 2016
  3. "Debiopharm investit. "J'ai fondé cette entreprise à Martigny", se souvient Rolland-Yves Mauvernay". Canal9 (in French). 2015-09-17. Retrieved 2023-02-13.
  4. "Spezialist für Entwicklung von Krebsmedikamenten – Klein und unbekannt, aber hochprofitabel Ein Generalunternehmer für die Pharmaindustrie". Finanz und Wirtschaft (in German). Retrieved 2023-02-17.
  5. Group, Debiopharm. "Debiopharm International SA Announces Phase III Positive Results for Triptorelin 6-month Formulation in the Management of Central Precocious Puberty (CPP)". www.prnewswire.com. Retrieved 2023-02-13.
  6. "Oxaliplatin - NCI". www.cancer.gov. 2006-10-05. Retrieved 2023-02-13.
  7. "Debiopharm". Debiopharm. Retrieved 2023-02-13.
  8. "Merck agrees $1 billion deal with Debiopharm for head and neck cancer drug". Reuters. 2021-03-01. Retrieved 2023-02-13.
  9. Frost & Sullivan Nov 25 2010 Movers & Shakers Interview with Maurice Wagner, Debiopharm Group
  10. Bloomberg profile: Debiopharm International. Page accessed May 12, 2016
  11. Bernard Tappy for In Vivo Magazine. 2013 Debiopharm Research and Manufacturing SA.
  12. Swiss Private Equity & Corporate Finance Association Debiopharm Investment SA Page accessed May 12, 2016
  13. "Digital Health Investment". Debiopharm. Retrieved 2022-09-13.
  14. "Triptorelin". drugs.com. Retrieved 11 November 2016.
  15. Taylor, Nick (24 May 2017). "Debiopharm buys ImmunoGen ADC to grow cancer pipeline". Fierce Biotech. Retrieved 23 June 2018.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.